Prescriptions and net revenue for Sofdra surged in Q4 FY26, with improved gross-to-net yield and a significant reduction in operating cash outflow. Cash reserves were strengthened by a capital raise, and strategic initiatives are underway to optimize sales force, supply chain, and IP portfolio.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.